Company research
Indaptus Therapeutics, Inc.
CIK 1857044Updated Sep 24, 2026
SecurityINDP · NASDAQ · equity
Name history
Intec Parent Inc. · through Aug 3, 2021
INDP price & chart
Loading TradingView…
NASDAQ:INDP on TradingView ↗In the news
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update ↗
Recent filings
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
424B5 filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 9,310,168Source | 7,338,756Source | 14,923,878Source | 28,063,806Source |
| Property, Plant and Equipment, NetUSD | — | — | 735Source | 2,019Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 8,507,628Source | 5,786,753Source | 13,362,053Source | 9,626,800Source |
| Assets, CurrentUSD | 9,310,168Source | 6,618,330Source | 13,995,209Source | 27,244,242Source |
| Prepaid Expense and Other Assets, CurrentUSD | 802,540Source | 831,577Source | 633,156Source | 811,433Source |
| Operating Lease, Right-of-Use AssetUSD | — | 82,175Source | 173,206Source | 79,294Source |
| Other Assets, NoncurrentUSD | — | 638,251Source | 754,728Source | 738,251Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | — | 3,393,881Source | 2,847,380Source | 3,433,341Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 10,000Source | — | — | — |
| Common Stock, Value, IssuedUSD | 21,674Source | 120,139Source | 84,011Source | 84,011Source |
| Additional Paid in CapitalUSD | 84,408,018Source | 64,263,919Source | 57,409,643Source | 54,443,705Source |
| Retained Earnings (Accumulated Deficit)USD | -81,288,099Source | -60,439,183Source | -45,417,156Source | -29,993,685Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | 96,434Source |
| Stockholders' Equity Attributable to ParentUSD | 3,151,593Source | 3,944,875Source | 12,076,498Source | 24,630,465Source |
| Liabilities and EquityUSD | 9,310,168Source | 7,338,756Source | 14,923,878Source | 28,063,806Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 6,158,575Source | 3,393,881Source | 2,774,032Source | 3,433,341Source |
| Operating Lease, Liability, CurrentUSD | — | 84,164Source | 101,705Source | 80,494Source |
| Accounts Payable, CurrentUSD | 544,057Source | 870,229Source | 806,004Source | 1,378,316Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 73,348Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,358,082Source | 2,305,849Source | 2,965,938Source | 2,957,249Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -14,823,256Source | -12,323,188Source | -13,405,315Source | -13,078,347Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | 17,140,568Source | -16,427,018Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 17,544,131Source | 4,747,888Source | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | — | 1,600Source | 1,600Source | 2,400Source |
| Additional Financial Items | ||||
| DepreciationUSD | — | 735Source | 1,284Source | 1,781Source |
| General and Administrative ExpenseUSD | 10,492,554Source | 8,114,654Source | 8,756,767Source | 8,586,249Source |
| Income Tax Expense (Benefit)USD | 1,716Source | 1,700Source | 2,450Source | 30Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | 96,434Source |
| Net Income (Loss) Attributable to ParentUSD | -20,848,916Source | -15,022,027Source | -15,423,471Source | -14,322,798Source |
| Nonoperating Income (Expense)USD | — | 343,724Source | 955,003Source | 588,108Source |
| Operating ExpensesUSD | 19,833,513Source | 15,365,751Source | 16,378,474Source | 14,910,906Source |
| Other Operating Income (Expense), NetUSD | 138,018Source | 343,724Source | — | — |
| Proceeds from Issuance of Common StockUSD | 6,396,888Source | 5,510,591Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -19,833,513Source | -15,365,751Source | -16,378,474Source | -14,910,906Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -20,847,194Source | — | — | — |
| Income Tax Expense (Benefit)USD | 1,716Source | 1,700Source | 2,450Source | 30Source |
| Net Income (Loss) Attributable to ParentUSD | -20,848,916Source | -15,022,027Source | -15,423,471Source | -14,322,798Source |
| Earnings Per Share, BasicUSD per share | -21.58Source | -1.61Source | -1.83Source | -1.73Source |
| Earnings Per Share, DilutedUSD per share | -21.58Source | -1.61Source | -1.83Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 966,124Source | 9,355,710Source | 8,401,047Source | 8,262,119Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 966,124Source | 9,355,710Source | 8,401,047Source | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 1,716Source | — | — | — |
| General and Administrative ExpenseUSD | 10,492,554Source | 8,114,654Source | 8,756,767Source | 8,586,249Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -21,447,994Source | — | — | — |
| Nonoperating Income (Expense)USD | — | 343,724Source | 955,003Source | 588,108Source |
| Operating ExpensesUSD | 19,833,513Source | 15,365,751Source | 16,378,474Source | 14,910,906Source |
| Other Operating Income (Expense), NetUSD | 138,018Source | 343,724Source | — | — |
| Research and Development ExpenseUSD | 9,340,959Source | 7,251,097Source | 7,621,707Source | 6,324,657Source |
Filing attachments
ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (August 13, 2026) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, today announced financial results for the second quarter and six months ended June 30, 2026, and provided a corporate update. Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and C…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (May 15, 2026) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the first quarter ended March 31, 2026, and provided a strategic corporate update. Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board, commente…
Read attachment ↗